Polaris Capital Management LLC Grows Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Polaris Capital Management LLC grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,500 shares during the period. Polaris Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $1,700,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Segall Bryant & Hamill LLC bought a new position in Supernus Pharmaceuticals in the third quarter worth about $791,000. Geode Capital Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the period. Franklin Resources Inc. boosted its position in shares of Supernus Pharmaceuticals by 7.6% during the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 2,121 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Supernus Pharmaceuticals by 40.6% in the third quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after purchasing an additional 73,118 shares in the last quarter.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent analyst reports. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price on the stock.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $37.93 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of 35.45 and a beta of 0.90. The firm has a 50-day moving average of $37.38 and a two-hundred day moving average of $34.90.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.